Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications ; volume:21 ; number:1 ; day:17 ; month:5 ; year:2019 ; pages:1-14 ; date:12.2019
Breast cancer research ; 21, Heft 1 (17.5.2019), 1-14, 12.2019
- Urheber
-
Jézéquel, Pascal
Kerdraon, Olivier
Hondermarck, Hubert
Guérin-Charbonnel, Catherine
Lasla, Hamza
Gouraud, Wilfried
Canon, Jean-Luc
Gombos, Andrea
Dalenc, Florence
Delaloge, Suzette
Lemonnier, Jérôme
Loussouarn, Delphine
Verrièle, Véronique
Campone, Mario
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-019-1148-6
- URN
-
urn:nbn:de:101:1-2019100903033370118371
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jézéquel, Pascal
- Kerdraon, Olivier
- Hondermarck, Hubert
- Guérin-Charbonnel, Catherine
- Lasla, Hamza
- Gouraud, Wilfried
- Canon, Jean-Luc
- Gombos, Andrea
- Dalenc, Florence
- Delaloge, Suzette
- Lemonnier, Jérôme
- Loussouarn, Delphine
- Verrièle, Véronique
- Campone, Mario
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Recent advances in therapeutic strategies for triple-negative breast cancer
A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
The value of dynamic contrast-enhanced MRI in differentiating triple-negative breast cancer from other subtypes
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Recent advances in therapeutic strategies for triple-negative breast cancer
A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
The value of dynamic contrast-enhanced MRI in differentiating triple-negative breast cancer from other subtypes
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Recent advances in therapeutic strategies for triple-negative breast cancer
A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women
The value of dynamic contrast-enhanced MRI in differentiating triple-negative breast cancer from other subtypes
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities